Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
13 p, 471.4 KB Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) : A Randomized, Open-Label, Phase III Trial / Dimopoulos, Meletios (National and Kapodistrian University of Athens) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Nahi, Hareth (Department of Medicine. Karolinska University) ; San-Miguel, J (Clínica Universidad de Navarra) ; Bahlis, Nizar J. (University of Calgary) ; Usmani, S. Z (Memorial Sloan Kettering Cancer Center) ; Rabin, Neil (Department of Haematology. University College London Hospitals NHS Trust) ; Orlowski, Robert Z. (Department of Lymphoma and Myeloma. The University of Texas) ; Suzuki, Kenshi (Department of Hematology. Japanese Red Cross Medical Center) ; Plesner, Torben (University of Southern Denmark) ; Yoon, Sung Soo (Department of Internal Medicine. Seoul National University) ; Ben Yehuda, Dina (Hematology Department. Hebrew University) ; Richardson, Paul G. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ; Goldschmidt, Hartmut (Heidelberg University Hospital (Alemanya)) ; Reece, Donna (Department of Medical Oncology and Hematology. Princess Margaret Cancer Centre) ; Ahmadi, Tahamtan (Genmab US (Estats Units d'Amèrica)) ; Qin, Xiang (Janssen Research & Development (Xina)) ; Garvin Mayo, Wendy (Janssen Research & Development (Estats Units d'Amèrica)) ; Gai, Xue (Janssen Research & Development (Estats Units d'Amèrica)) ; Carey, Jodi (Janssen Research & Development (Estats Units d'Amèrica)) ; Carson, Robin (Janssen Research & Development (Estats Units d'Amèrica)) ; Moreau, Philippe (Hematology Department. University Hospital Hôtel-Dieu)
PURPOSEWith the initial analysis of POLLUX at a median follow-up of 13. 5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2023 - 10.1200/JCO.22.00940
Journal of Clinical Oncology, Vol. 41 Núm. 8 (october 2023) , p. 1590-1599  

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.